再心生物科技公司的人类心室心肌组织 (hvCTS) 是专用于测定在药物和疾病影响下的人类心脏收缩性状况的模型。
- 高敏感度並可靠地預測药物和病原對心脏收缩力的影响
- 定制生物反应器只需最简短的操作指示便可容許组织制造和实现性能的测定
- 能够不用在精密仪器下直接测量心肌的抽动力
- 探测力量的集成传感器能提供对心肌组织连续长时间的纵向研究
人类心室心肌组织包含两种型号可供选购:
- (生产批号：3-01) 生物反应器模具
- (生产批号：3-02) 药物筛查 / 测定人类心肌收缩性的全面配置（包括必要的生物反应器、试剂以及细胞）
- 心脏致毒成分筛查: 鉴定对人类心室心肌组织具变时性和正性肌力的作用剂。
- 疾病建模: 对多种人类心肌病提供实用可观测性的特征。
- 药物研发, 药物筛查及对具变时性和正性肌力物质的疗效评估。
- 再生研究: 可供研究人类心肌细胞收缩性成熟度, 治疗机制和修复损伤了的人类心脏肌肉的可行性。
Lee, E. K., Tran, D. D., Keung, W., Chan, P., Wong, G., Chan, C. W., Costa, K. D., Li, R. A. & Khine, M. Machine learning of human pluripotent stem cell-derived engineered cardiac tissue contractility for automated drug classification. Stem Cell Reports. 9, 1560-1572 (2017).
Zhang, W., Kong, C. W., Tong, M. H., Chooi, W. H., Huang, N., Li, R. A., Chan, B. P. Maturation of human embryonic stem cell-derived cardiomyocytes (hESC-CMs) in 3D collagen matrix: Effects of niche cell supplementation and mechanical stimulation. Acta Biomater. 49, 204-217 (2017).
Keung, W., Ren, L., Sen Li, Wong, A. O., Chopra, A., Kong, C. W., Tomaselli, G. F., Chen, C. S., Li, R. A. Non-cell autonomous cues for enhanced functionality of human embryonic stem cell-derived cardiomyocytes via maturation of sarcolemmal and mitochrondrial K(ATP) channels. Sci Rep. 6, 34154 (2016).
Cashman, T. J., Josowitz, R., Gelb, B. D., Li, R. A., Dubois, N. C., Costa, K. D., Construction of Defined Human Engineered Cardiac Tissues to Study Mechanisms of Cardiac Cell Therapy. J Vis Exp. 109, e53447 (2016).
Cashman, T. J., Josowitz, R., Johnson, B. V, Gelb, B. D. & Costa, K. D. Human Engineered Cardiac Tissues Created Using Induced Pluripotent Stem Cells Reveal Functional Characteristics of BRAF-Mediated Hypertrophic Cardiomyopathy. PLoS One 1–17 (2016).
Karakikes, I., Stillitano, F., Nonnenmacher, M., Tzimas, C., Sanoudou, D., Termglinchan, V., Kong, C. W., Rushing, S., Hansen, J., Ceholski, D., Kolokathis, F., Kremastinos, D., Katoulis, A., Ren, L., Cohen, N., Gho, J. M., Tsiapras, D., Vink, A., Wu, J. C., Asselbergs, F. W., Li, R. A., Hulot, J. S., Kranias, E. G., Hajjar, R. J. Correction of human phospholamban R14del mutation associated with cardiomyopathy using targeted nucleases and combination therapy. Nat Commun. 6, 6955 (2015).
Chen, G., Li, S., Karakikes, I., Ren, L., Chow, M. Z., Chopra, A., Keung, W., Yan, B., Chan, C. W. Y., Costa, K. D., Kong, C., Hajjar, R. J., Chen, C. S. & Li, R. A. Phospholamban as a Crucial Determinant of the Inotropic Response of Human Pluripotent Stem Cell – Derived Ventricular Cardiomyocytes and Engineered 3-Dimensional Tissue Constructs. Circ Arrhythm Electrophysiol 8, 193–202 (2015).
Turnbull, I. C., Karakikes, I., Serrao, G. W., Backeris, P., Lee, J. J., Xie, C., Senyei, G., Gordon, R. E., Li, R. A., Akar, F. G., Hajjar, R. J., Hulot, J. & Costa, K. D. Advancing functional engineered cardiac tissues toward a preclinical model of human myocardium. FASEBJ. 28, 644–654 (2014).
Serrao, G. W., Turnbull, I. C., Ancukiewicz, D., Kim, D. E., Kao, E., Cashman, T. J., Hadri, L., Hajjar, R. J. & Costa, K. D. Myocyte-depleted engineered cardiac tissues support therapeutic potential of mesenchymal stem cells. Tissue Eng. Part A 18, 1322–1333 (2012).
| 生产批号 |
产品名称 |
数量 |
|
| 3-0101 |
生物反应器模具 x 5 |
1
|
查询报价 |
| 3-0102 |
生物反应器模具 x 50 |
1
|
查询报价 |
| 3-0103 |
药物筛查 / 测定人类心肌收缩性的全面配置 (10條心肌组织)
心肌组织用於测试一种药物 (一种浓度) , 根据我们的标准会引用超过七成純度的人类心肌细胞 |
1
|
查询报价 |
| 3-0104 |
药物筛查 / 测定人类心肌收缩性的全面配置 (20條心肌组织)
心肌组织用於测试一种药物 (一种浓度) , 根据我们的标准会引用超过七成純度的人类心肌细胞 |
1 |
查询报价 |
How many cardiomyocytes are needed for constructing one tissue strip?
Approximately 1 million hvCMs are needed for each tissue strip.
When can the tissue strip be used for the contractility assay?
We recommend allowing tissue strips to develop for 5 to 7 days after creation before the first contractility assay.
How can the bioreactor molds be sterilized?
We recommend sterilization by autoclaving.
Are the bioreactor molds reusable?
Yes. However, we recommend that the molds to be replaced after 5 uses.
